Análises clínicas e monitoramento do infliximabe em doenças inflamatórias intestinais pediátricas
Barra lateral de artigos
Conteúdo do artigo principal
Resumo
Introdução: As doenças inflamatórias intestinais (DIIs) são um grupo de de difícil diagnóstico e monitoramento. Elas são divididas em 2 grupos mais comuns, sendo estes a retocolite ulcerativa e a doença de Crohn. Existe ainda o grupo de doenças inflamatórias intestinais não-classificadas. Em crianças, as DIIs podem resultar em atraso no desenvolvimento e crescimento, seja pela perda de peso, por diminuição da densidade óssea ou ainda por atrasos na puberdade.
Objetivo: Comparar exames laboratoriais de pacientes pediátricos durante os períodos de indução e manutenção do tratamento das DIIs com Infliximabe.
Método: Pesquisa de natureza quantitativa, de cunho analítico e observacional de coorte. Foram avaliados os valores de hemoglobina, leucócitos totais, número de plaquetas, albumina, velocidade de hemossedimentação e proteína C-reativa de 11 pacientes.
Resultado: Na coleta referente ao período de indução, 5 pacientes apresentavam baixa hemoglobina, 3 com valores aumentados de leucócitos e 5 com aumento do número de plaquetas/Ul. Ainda referente ao período de indução, foi observada diminuição de albumina sérica em 5 laudos e aumento dos valores de PCR também em 5. Os valores de VHS estavam aumentados em todos os prontuários.
Conclusão: Foi possível observar melhora dos parâmetros no período de manutenção com relação ao período de indução.
Detalhes do artigo
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.
Referências
Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20(1):91-9. https://doi.org/10.3748/wjg.v20.i1.91
Rosen MJ, Dhawan A, Saeed SA. Inflammatory bowel disease in children and adolescents. JAMA Pediatr. 2015;169(11):1053-60. https://doi.org/10.1001/jamapediatrics.2015.1982
Thurgate LE, Lemberg DA, Day AS, Leach ST. An overview of inflammatory bowel disease unclassified in children. Inflamm Intest Dis. 2019;4(3):97-103. https://doi.org/10.1159/000501519
Roda G, Chien Ng S, Kotze PG, Argollo M, Panaccione R, Spinelli A, et al. Crohn's disease. Nat Rev Dis Primers. 2020;6(1):22. https://doi.org/10.1038/s41572-020-0156-2
Galgut BJ, Lemberg DA, Day AS, Leach ST. The value of fecal markers in predicting relapse in inflammatory bowel diseases. Front Pediatr. 2018;5:292. https://doi.org/10.3389/fped.2017.00292
Chang S, Malter L, Hudesman D. Disease monitoring in inflammatory bowel disease. World J Gastroenterol. 2015;21(40):11246-59. https://doi.org/10.3748/wjg.v21.i40.11246
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn's disease. Lancet. 2017;389(10080):1741-55. https://doi.org/10.1016/S0140-6736(16)31711-1
Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. Lancet. 2017;389(10080):1756-70. https://doi.org/10.1016/S0140-6736(16)32126-2
Cai Z, Wang S, Li J. Treatment of inflammatory bowel disease: a comprehensive review. Front Med (Lausanne). 2021;8:765474. https://doi.org/10.3389/fmed.2021.765474
Bouhuys M, Lexmond WS, van Rheenen PF. Pediatric inflammatory bowel disease. Pediatrics. 2023;151(1):e2022058037. https://doi.org/10.1542/peds.2022-058037
Conrad M, Kelsen J. The treatment of pediatric inflammatory bowel disease with biologic therapies. Curr Gastroenterol Rep. 2020;22(8):36. https://doi.org/10.1007/s11894-020-00773-3
Mitoma H, Horiuchi T, Tsukamoto H, Ueda N. Molecular mechanisms of action of anti-TNF-α agents: comparison among therapeutic TNF-α antagonists. Cytokine. 2018;101:56-63. https://doi.org/10.1016/j.cyto.2016.08.014
Turner D, Ruemmele FM, Orlanski-Meyer E, Griffiths AM, de Carpi JM, Bronsky J, et al. Management of paediatric ulcerative colitis, part 1: ambulatory care – an evidence-based guideline from European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;67(2):257-91. https://doi.org/10.1097/MPG.0000000000002035
van Rheenen PF, Aloi M, Assa A, Bronsky J, Escher JC, Fagerberg UL, et al. The medical management of paediatric Crohn's disease: an ECCO-ESPGHAN guideline update. J Crohns Colitis. 2021;15(2):jjaa161. https://doi.org/10.1093/ecco-jcc/jjaa161
Mahadea D, Adamczewska E, Ratajczak AE, Rychter AM, Zawada A, Eder P, et al. Iron deficiency anemia in inflammatory bowel diseases – a narrative review. Nutrients. 2021;13(11):4008. https://doi.org/10.3390/nu13114008
Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis. 2000;6(2):142-50. https://doi.org/10.1097/00054725-200005000-00013
Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med. 2004;116 Suppl 7A:44S-49S. https://doi.org/10.1016/j.amjmed.2003.12.011
Sadi G, Yang Q, Dufault B, Stefanovici C, Stoffman J, El-Matary W. Prevalence of peripheral eosinophilia at diagnosis in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2016;62(4):573-6. https://doi.org/10.1097/MPG.0000000000000957
Zhou Y, Huang Y. Inflammatory bowel disease in Chinese children: a retrospective analysis of 49 cases. Exp Ther Med. 2016;12(5):3363-8. https://doi.org/10.3892/etm.2016.3756
Tiede I, Fritz G, Strand S, Poppe D, Dvorsky R, Strand D, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest. 2003;111(8):1133-45. https://doi.org/10.1172/JCI16432
Kulnigg-Dabsch S, Schmid W, Howaldt S, Stein J, Mickisch O, Waldhor T, et al. Iron deficiency generates secondary thrombocytosis and platelet activation in IBD: the randomized, controlled thromboVIT trial. Inflamm Bowel Dis. 2013;19(8):1609-16. https://doi.org/10.1097/MIB.0b013e318281f4db
Mack DR, Langton C, Markowitz J, Leleiko N, Griffiths A, Bousvaros A, et al. Laboratory values for children with newly diagnosed inflammatory bowel disease. Pediatrics. 2007;119(6):1113-9. https://doi.org/10.1542/peds.2006-1865
Wong K, Isaac DM, Wine E. Growth delay in inflammatory bowel diseases: significance, causes, and management. Dig Dis Sci. 2021;66(4):954-64. https://doi.org/10.1007/s10620-020-06759-5
Bray C, Bell LN, Liang H, Haykal R, Kaiksow F, Mazza JJ, et al. Erythrocyte sedimentation rate and C-reactive protein measurements and their relevance in clinical medicine. WMJ. 2016;115(6):317-21.
Soubières AA, Poullis A. Emerging biomarkers for the diagnosis and monitoring of inflammatory bowel diseases. Inflamm Bowel Dis. 2016;22(8):2016-22. https://doi.org/10.1097/MIB.0000000000000836
Alper A, Zhang L, Pashankar DS. Correlation of erythrocyte sedimentation rate and C-reactive protein with pediatric inflammatory bowel disease activity. J Pediatr Gastroenterol Nutr. 2017;65(2):e25-7. https://doi.org/10.1097/MPG.0000000000001444
Consigny Y, Modigliani R, Colombel JF, Dupas JL, Veyrac M, Gendre JP, et al. A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm Bowel Dis. 2006;12(7):551-7. https://doi.org/10.1097/01.ibd.0000225334.60990.5b
Wagatsuma K, Yokoyama Y, Nakase H. Role of biomarkers in the diagnosis and treatment of inflammatory bowel disease. Life (Basel). 2021;11(12):1375. https://doi.org/10.3390/life11121375